Stock Events

Stock Events

Relmada Therapeutics 

$4.33
40
-$0.19-4.2% 20:00 Today
+$0.16+3.67%20:10After hours

Statistics

Day High
4.52
Day Low
4.32
52W High
8
52W Low
0.822
Volume
678,358
Avg. Volume
1,736,931
Mkt Cap
461.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.67
-0.49
-0.3
-0.11
Expected EPS
-0.141367
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-57.39MNet Income

Analyst Ratings

14.25Average Price Target
The highest estimate is 19.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RLMD. It's not an investment recommendation.
Alphabet
7
GOOGL
Microsoft
6
MSFT
Tesla
6
TSLA
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap8.11B
Alkermes develops treatments for major depressive disorder and other central nervous system disorders, overlapping with Relmada's focus.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson, through its pharmaceutical division Janssen, offers products that compete in the mental health space.
Lilly(Eli) &
LLY
Mkt Cap1.12T
Eli Lilly has a strong portfolio in psychiatric and neurological conditions, directly competing with Relmada's offerings.
Pfizer
PFE
Mkt Cap159.99B
Pfizer has a broad range of products for neurological and psychiatric conditions, making it a competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap43.51B
Teva Pharmaceutical Industries has a focus on CNS and pain, areas that Relmada is also targeting.
Novartis
NVS
Mkt Cap301.95B
Novartis offers medications for a wide range of neurological conditions, competing in the same market as Relmada.
Merck
MRK
Mkt Cap376.37B
Merck & Co. has initiatives in brain health, including treatments for conditions that Relmada targets.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie has a growing portfolio in neuroscience, including treatments for psychiatric disorders.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol Myers Squibb has a diverse neuroscience portfolio, making it a competitor in the mental health treatment market.

About

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Show more...
CEO
Sergio Traversa
Employees
17
Country
United States
ISIN
US75955J4022
WKN
000A2PSZF

Listings

STU
DE
4E2.STU
F
DE
4E2.F
MU
DE
4E2.MU
XNAS
US
RLMD

0 Comments

Share your thoughts

FAQ

What is Relmada Therapeutics stock price today?▼
The current price of RLMD is $4.33 USD — it has decreased by -4.2% in the past 24 hours. Watch Relmada Therapeutics stock price performance more closely on the chart.
What is Relmada Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Relmada Therapeutics stocks are traded under the ticker RLMD.
Is Relmada Therapeutics stock price growing?▼
RLMD stock has fallen by -6.48% compared to the previous week, the month change is a -17.21% fall, over the last year Relmada Therapeutics has showed a +458.71% increase.
What is Relmada Therapeutics market cap?▼
Today Relmada Therapeutics has the market capitalization of 461.88M
When is the next Relmada Therapeutics earnings date?▼
Relmada Therapeutics is going to release the next earnings report on November 05, 2026.
What were Relmada Therapeutics earnings last quarter?▼
RLMD earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.2 USD resulting in a +44.87% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Relmada Therapeutics revenue for the last year?▼
Relmada Therapeutics revenue for the last year amounts to 0 USD.
What is Relmada Therapeutics net income for the last year?▼
RLMD net income for the last year is -57.39M USD.
How many employees does Relmada Therapeutics have?▼
As of August 28, 2026, the company has 17 employees.
In which sector is Relmada Therapeutics located?▼
Relmada Therapeutics operates in the Health & Wellness sector.
When did Relmada Therapeutics complete a stock split?▼
The last stock split for Relmada Therapeutics was on September 30, 2019 with a ratio of 1:4.
Where is Relmada Therapeutics headquartered?▼
Relmada Therapeutics is headquartered in CORAL GABLES, United States.